In an interview with Targeted Oncology ®, Stefania Morganti, MD, PhD, research fellow at the Dana-Farber Cancer Institute, addressed the current clinical utility and inherent limitations of using ...
Minimal residual disease (MRD)—minute populations of cancer cells undetectable by conventional imaging—remains the chief driver of relapse for patients. For years, detecting MRD has relied on invasive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback